Change in Urine Albumin-to-Creatinine Ratio May Be a Prognostic Indicator in T2D

Share this content:
Early changes in albuminuria may portend the risk of subsequent cardiovascular and renal events in patients with diabetes.
Early changes in albuminuria may portend the risk of subsequent cardiovascular and renal events in patients with diabetes.

Increased urine albumin-to-creatinine ratio (UACR) over a 2-year period independently predicted adverse cardiovascular and renal outcomes, as well as all-cause mortality, in a study conducted in patients with type 2 diabetes (T2D). Decreased UACR was not found to significantly predict lower risk of clinical outcomes, according to the research published in Diabetes Care. However, after accounting for regression to the mean (RtM), associations between decreases in UACR and study outcomes were much stronger and reached significance for all outcomes excluding major renal events.

The aim of this investigation — which evaluated 8766 participants in ADVANCE-ON (the posttrial follow-up to the Action in Diabetes and Vascular Disease: preterAx and diamicroN-MR Controlled Evaluation study) — was to assess the associations among 2-year changes in UACR and major cardiovascular events, renal events, and all-cause mortality associated with T2D.

 

Investigators took UACR measurements of the participants 2 years apart and then segmented the results into 3 classification groups: ≥30% decrease in UACR, minor change, or ≥30% increase in UACR. Analyses were repeated to take into account regression to the mean (RtM).

An increase in UACR over 2 years predicted a greater risk of adverse clinical outcomes (hazard ratio [HR] for ≥30% UACR increase vs minor change: 1.26; 95% CI, 1.13-1.41).

More specifically, an increase in UACR was significantly associated with a 20% higher risk of major macrovascular events (95% CI, 5%-38%), a 67% higher risk of major renal events (95% CI, 2%-273%), and a 40% increased risk of all-cause mortality (95% CI, 22%-60%).

 

Although decrease in UACR over 2 years was not found to be significantly related to a lower risk of adverse clinical outcomes (HR 0.93; 95% CI, 0.83-1.04), adjustment for RtM revealed the “actual” decrease to be significantly related to lowered risks (HR 0.84; 95% CI, 0.75-0.94).

“Our results suggest that clinically meaningful changes in UACR, up or down, may translate to corresponding changes in the risk of future major clinical outcomes and death in people with T2D,” investigators concluded.

The study used multiple approaches to determine the association between change in UACR and clinically meaningful outcomes, which the researchers describe as a strength of the study design, as was the diverse and large study population.

Investigators cited the UACR measurement, which often has sizeable within-person variability, as a limitation.

Reference

Jun M, Ohkuma T, Zoungas S, et al; on behalf of the ADVANCE Collaborative Group. Changes in albuminuria and the risk of major clinical outcomes in diabetes: results from ADVANCE-ON [published online October 27, 2017]. Diabetes Care. doi: 10.2337/dc17-1467

 

You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters

CME Focus